Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: out_of_the_loop who wrote (2709)	8/1/1999 5:53:00 PM
From: Bradpalm1	Read Replies (1) \| Respond to of 10293

Dr. Epstein, I'll review this JAMA article as I pursue this further, but this ICAM-1 receptor blockage theory seems too simplistic given the complex contribution of other known immunomodulators such as IgA and numerous interferon molecules. Recombinant trickery is interesting, but by no means yet a "proof" of this model. What's to argue against this proposed receptor blockage mechanism as being simply a epiphenomenon? The listed references I reviewed on the Zicam website aren't particularly persuasive or do you find them so? Are you proposing the mass effect of retail market distribution as support for your position?